Genome editing-based therapies typically aim to treat disease by correcting underlying genetic mutations in patient's cells.
INSTALL results showed successful and safe non-viral insertion of large genetic payloads in the livers of mice when delivered by lipid nanoparticles (LNPs). In contrast, mice experienced fatal immune ...
Tome Biosciences is leading the field of programmable genomic integration (PGI). Building on founding technologies obtained from MIT and Replace Therapeutics, Tome has developed and refined PGI ...
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...
David Liu and Richard Merkin of the Broad Institute of MIT and Harvard, along with Columbia professor Sam Sternberg, have developed a new, targeted means of inserting entire genes into human DNA ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
Scientists at the Broad Institute of MIT and Harvard have improved a gene-editing technology that is now capable of inserting or substituting entire genes in the genome in human cells efficiently ...
Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or inactivating genes. Precisely fixing disease-causing mutations is far more ...
Earth's biodiversity is in crisis. An imminent "sixth mass extinction" threatens beloved and important wildlife. It also threatens to reduce the amount of genetic diversity—or variation—within species ...
Poseida Therapeutics is a biopharmaceutical company specializing in cell and gene therapies for cancer and genetic conditions. The company's proprietary gene editing and delivery platforms show ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results